Ogawa H, Kunoh Y, Sugiura T, Nagasaka M
New Drug Research Laboratory, Maruko Pharmaceutical Co., Ltd., Aichi, Japan.
Life Sci. 1992;50(5):375-81. doi: 10.1016/0024-3205(92)90439-v.
MTP-3631 is a novel thiopyranopyrimidine derivative structurally different from any existent hypoglycemic agents. MTP-3631 markedly decreased basal blood glucose and improved glucose intolerance in genetically diabetic C57BL/6J ob/ob mice, which was not affected by tolbutamide. MTP-3631 also caused hypoglycemic effects in normal rats, but no change was observed in plasma insulin level. Unlike buformin, MTP-3631 did not change plasma lactate level in ob/ob mice. These results suggest that the hypoglycemic mechanism of MTP-3631 may be essentially different from those of sulfonylureas and biguanides.
MTP - 3631是一种新型的硫代吡喃并嘧啶衍生物，其结构与任何现有的降血糖药物都不同。MTP - 3631显著降低了遗传性糖尿病C57BL / 6J ob/ob小鼠的基础血糖，并改善了葡萄糖耐量，而甲苯磺丁脲对此没有影响。MTP - 3631在正常大鼠中也产生了降血糖作用，但血浆胰岛素水平未观察到变化。与二甲双胍不同，MTP - 3631不会改变ob/ob小鼠的血浆乳酸水平。这些结果表明，MTP - 3631的降血糖机制可能与磺脲类和双胍类药物的降血糖机制本质上不同。
